戻る Agenda
Session2: Clinical Trial Model in Post COVID-19
Session Chair(s)
Toshiko Ishibashi, PHD, RN
Oncology Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd., Japan
Eri Sekine
Executive Vice President Data Business, CMIC Co., Ltd, Japan
Speaker(s)
Mark Scullion
Global Head Trial Monitoring,, Novartis Corporation, United States
Recasting the Model in a Post-COVID World
Kazumi Yabe
Clinical Operations, Bristol-Myers Squibb, Japan
Proposal from TransCelerate; Modernizing Clinical Trial Conduct
Dai Nagaki
Clincial Leader, Clinical Research Dept. , CMIC Co., Ltd., Japan
The Impact of COVID-19 on Clinical Trial Activities from the CRO Perspective
Yasutoshi Kuboki, MD, PHD
Experimental Therapeutics, National Cancer Center Hospital East, Japan
Clinical Trial Model in Post COVID-19 - Site Perspectives
Elisabet Kim, MSN, RN
Project Manager, Asan Medical Center, Korea, Republic of
Experience of Clinical Trials during the COVID-19 Pandemic_CRC’s Perspective in Korea